103 results
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall
8-K
EX-10.2
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
and in connection with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery … of such qualifications, registrations and exemptions; (vii) if applicable, the filing fees incident to the review and approval by the FINRA of the Placement
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
of Common Stock. We will bear all fees and expenses incident to our obligation to register the shares of Common Stock.
The Selling Stockholders may sell
8-K
EX-10.2
758h7
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
5504148o
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-1.1
rgbjlhrvdozf
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B3
2w8 et4gfzoodbavh32
29 Sep 23
Prospectus supplement
4:56pm
8-K
EX-10.1
ag063v3z841fit56w1
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
8-K
EX-1.1
tf4bgdf7ptsiwij4h7u
12 May 22
Entry into a Material Definitive Agreement
8:31am
424B3
ebqo24qze2 vby
27 Dec 21
Prospectus supplement
5:01pm
8-K
EX-10.1
jh17wl4hji9p07el
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-1.1
p1k5i
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
8-K
EX-1.1
9e8fc
26 Jan 21
Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock
5:09pm